Ultragenyx Pharmaceutical Inc. of Novato, Calif., sold 4.4m shares at $57 each on Jan. 23 to gross $250m. The company did not specify how it would use the cash, which was raised in line with a shelf registration statement filed with the US Securities and Exchange Commission (SEC) in 2015. Ultragenyx launched its first product Mepsevii (vestronidase alfa-vjbk), a recombinant version of the enzyme beta-glucuronidase, for children and adults with the rare genetic disease Mucopolysaccharidosis VII (MPS VII or Sly syndrome) late last year. The company also is awaiting approvals for its next product burosumab for adults with X-linked hypophosphatemia (XLH), which has an April 17 PDUFA date in the US. (Also see "Ultragenyx Gets Commercial Feet Wet With Mepsevii Launch In Sly Syndrome" - Scrip, 16 November, 2017.)

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

More from Financing

More from Business